University of Texas Southwestern Medical Center

COMBINEDBrain announces the launch of Project FIND-OUT

Retrieved on: 
Mercoledì, Novembre 8, 2023
University of Texas Southwestern Medical Center, Genetic counseling, Whole genome sequencing, MIT, Genomics, Genetic testing, Assistant, Kennedy Krieger Institute, Life, Hope, Family, Children's National Hospital, MD, Neurology, Angelman syndrome, Genetics, Psychiatry, Patient, Harvard University, Pediatrics, DSM-IV codes, Broad Institute, BCL, WGS, Travel, Diagnosis, GEM, Child, Medical device, Project

BRENTWOOD, Tenn., Nov. 8, 2023 /PRNewswire/ -- COMBINEDBrain, a non-profit organization dedicated to fast-tracking cures for neurodevelopmental disorders, today announced the launch of Project FIND-OUT (Fast Infant Neurodevelopmental Diagnosis via Outpatient Testing), a collaboration among leading non-profit, academic, and industry organizations.

Key Points: 
  • BRENTWOOD, Tenn., Nov. 8, 2023 /PRNewswire/ -- COMBINEDBrain, a non-profit organization dedicated to fast-tracking cures for neurodevelopmental disorders, today announced the launch of Project FIND-OUT (Fast Infant Neurodevelopmental Diagnosis via Outpatient Testing), a collaboration among leading non-profit, academic, and industry organizations.
  • Project FIND-OUT provides whole genome sequencing (WGS) to infants who have early symptoms of rare genetic neurodevelopmental disorders.
  • Project FIND-OUT purchased BCL's $1,000 clinical WGS services offering which is a collaboration between BCL and Fabric Genomics leveraging the Fabric Genomics' GEM AI interpretation technology.
  • Project FIND-OUT is unique in that it provides free whole genome sequencing, genetic counseling, and referral to specialists for symptomatic infants who meet straightforward inclusion criteria.

Mary Kay Ash Foundation℠ Celebrates Five Years Shaping the Future of Cancer Research in Partnership With UT Southwestern Medical Center

Retrieved on: 
Martedì, Novembre 7, 2023
Cosmetics, Retail, Oncology, Women, Philanthropy, Hospitals, Catalog, Fund Raising, Foundation, Science, Other Philanthropy, Other Science, Consumer, Research, Health, Fashion, Knowledge, University of Texas Southwestern Medical Center, Human, São Paulo, Publication, AUC, Front Row, Multimedia, Mentorship, Partnership, Cancer, Cell biology, University, Woman, Class, Harold, Shanghai Jiao Tong University, Pharmaceutical industry, Nursing, Geriatrics

Hosted at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, the fellowship is a two-year postdoctoral program sponsored by the Mary Kay Ash Foundation.

Key Points: 
  • Hosted at the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, the fellowship is a two-year postdoctoral program sponsored by the Mary Kay Ash Foundation.
  • View the full release here: https://www.businesswire.com/news/home/20231107256704/en/
    International Postdoctoral Scholars in Cancer Research, Class of 2023.
  • “For more than two decades, the Mary Kay Ash Foundation and UT Southwestern Medical Center have partnered in a continued commitment to find cures for cancers affecting women,” said Michael Lunceford, President, Mary Kay Ash Foundation Board of Directors.
  • “We appreciate Mary Kay Ash Foundation’s continued investment in UT Southwestern Medical Center and the future of cancer research.

CymaBay Announces Publication of Two-year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

Retrieved on: 
Mercoledì, Novembre 1, 2023
McWherter, Liver injury, Patient, University of Texas Southwestern Medical Center, AST, MD, Conditional sentence, Liver, Professor, ALP, PBC, Bilirubin, Vierling, Alkaline phosphatase, Cholestasis, Primary biliary cholangitis, University, Safety, Alimentary Pharmacology & Therapeutics, Therapy, ALT, Diagnosis, Liver disease, Pharmaceutical industry, DA, RJ, Y, PJ

Patients with PBC were eligible to enroll in this long-term extension study if they had successfully completed a prior study of seladelpar.

Key Points: 
  • Patients with PBC were eligible to enroll in this long-term extension study if they had successfully completed a prior study of seladelpar.
  • The objectives were to evaluate the long-term safety, tolerability, and efficacy of seladelpar at 5 mg and 10 mg once daily throughout 2-years.
  • In addition, ALP normalization was achieved in 23% and 42% in patients at one and two years, respectively.
  • In the study long-term treatment with seladelpar resulted in continued improvement in markers of cholestasis and liver injury in the second year of treatment.

Castle Announces Early Exploratory Study Data for Potential Development of a Complementary Test to Accompany DecisionDx®-UM That Could Aid in the Early Detection of Uveal Melanomas

Retrieved on: 
Venerdì, Novembre 3, 2023
Other Health, Research, General Health, Optical, Oncology, Medical Devices, Clinical Trials, Science, Biotechnology, Medical Supplies, Other Science, Health, University of Texas Southwestern Medical Center, Uveal melanoma, Biomarker, Ophthalmology, AAO, Malignancy, Risk, Eye, Patient, Pharmaceutical industry, Medical imaging

Harbour is a leading innovator in the treatment and study of uveal melanoma and the original developer of the DecisionDx-UM test, which he licensed to Castle in 2009.

Key Points: 
  • Harbour is a leading innovator in the treatment and study of uveal melanoma and the original developer of the DecisionDx-UM test, which he licensed to Castle in 2009.
  • “Unfortunately, this approach is highly subjective and can lead to both under- and over-treatment of patients.
  • The presentation details are as follows:
    Castle expects to share additional updates in 2024 on the ongoing exploratory study and potential development of a complementary test.
  • An excerpt from Schefler’s presentation regarding the study can be viewed here .

Genascence Names Ian Lachlan McLean, M.D. Ph.D. as Chief Medical Officer

Retrieved on: 
Mercoledì, Ottobre 18, 2023
Science, University of Texas Southwestern Medical Center, AstraZeneca, IND, Molecular biology, Biomarker, Human, Genetics, Takeda, Investigational New Drug, University, CTA, Merck, PALO, Inflammation, Research, R, Drug development, McLean, DSM-IV codes, Novomer, Medicine, Russell Travers, Osteoarthritis, Patient, Doctor of Philosophy, Pharmaceutical industry, Lachy, Genentech

PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Ian Lachlan (Lachy) McLean, M.D., Ph.D. as its chief medical officer. Dr. McLean brings extensive leadership experience in both early and late-stage clinical research and development (R&D) in the biopharmaceutical space, as well as complimentary clinical practice expertise as a rheumatologist to Genascence. He will lead Genascence's clinical development strategy.

Key Points: 
  • —Seasoned physician-scientist and R&D executive, with significant experience building and growing successful clinical development organizations—
    PALO ALTO, Calif., Oct. 18, 2023 /PRNewswire/ -- Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced the appointment of Ian Lachlan (Lachy) McLean, M.D., Ph.D. as its chief medical officer.
  • "On behalf of the entire Genascence organization and board of directors, I am thrilled to welcome Lachy as our chief medical officer," said Thomas Chalberg, Ph.D., founder and CEO of Genascence.
  • "Genascence is at the forefront of transforming how we treat prevalent and debilitating musculoskeletal diseases like osteoarthritis with gene therapy," said Dr. McLean.
  • Before joining Genascence, Dr. McLean was chief medical officer at Novome, a start-up biotech company developing engineered bacteria as a drug-delivery platform.

Kamada Announces Recent Achievements with CYTOGAM® including Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

Retrieved on: 
Lunedì, Ottobre 16, 2023
Transfer, Kamada, Food, Division, CSL Behring, Research, University of Texas Southwestern Medical Center, Pancreas, Cytomegalovirus, Critical care, Liver, Heart, Holocene, Immunoglobulin G, Safety, University, Transplant, Survival, Tobacco Products Scientific Advisory Committee, FDA, Kidney, Food and Drug Administration, Lung, Availability, KMDA, TASE, Patient, CMV, Pharmaceutical industry

Kamada announced that CYTOGAM manufactured at the Company’s facility in Beit Kama, Israel, is now available for commercial sales in the U.S.

Key Points: 
  • Kamada announced that CYTOGAM manufactured at the Company’s facility in Beit Kama, Israel, is now available for commercial sales in the U.S.
  • This follows the recent FDA approval of the technology transfer process of CYTOGAM from its previous manufacturer, CSL Behring.
  • The availability of Kamada-manufactured CYTOGAM in Canada is expected later this year.
  • The advisory board focuses on Kamada’s newly implemented U.S. clinical program for CYTOGAM including new opportunities and future research and development possibilities.

Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting

Retrieved on: 
Martedì, Ottobre 10, 2023
General Health, Health, Other Health, CDT, American Red Cross, Central Time Zone, Abstract, University of Texas Southwestern Medical Center, UCSF Medical Center, Transfusion medicine, University, Stanford University, Corporation, CERS, Use, Pharmaceutical industry, Vaccine, Cerus Corporation

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.
  • This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.
  • The following is a select list of presentations and abstracts of interest for Cerus.
  • Sunday, October 15, 2023 – 10:00 a.m.– Pathogen Reduced Cryoprecipitate: Early Experiences and Inventory Management Outcomes (Chair: M.S.

Coalition of Prominent Women Leaders Launches Women’s Heart Health Pledge to Demand Equitable Healthcare

Retrieved on: 
Domenica, Ottobre 8, 2023
Health, Consumer, Hospitals, Women, Other Health, Cardiology, Multimedia, Death, Thrive Global, Economics, University of Texas Southwestern Medical Center, Heart, Splenic infarction, Disease, American Heart Association, Education, University, The New York Times Magazine, Attention, AHA, Research, Dietary supplement, Pharmaceutical industry, Woman

Today, a coalition of women leaders and allies kicked off a national campaign to improve heart health for women, who are twice as likely to die from heart attacks as men.

Key Points: 
  • Today, a coalition of women leaders and allies kicked off a national campaign to improve heart health for women, who are twice as likely to die from heart attacks as men.
  • View the full release here: https://www.businesswire.com/news/home/20231008766508/en/
    The Women's Heart Health Pledge is part of an ongoing effort to transform the way we approach women's cardiovascular health through education and systemic change in healthcare.
  • The campaign will run indefinitely, with an unwavering commitment to effecting real and lasting change in women's heart health.
  • I stand for women being in control of their heart health, I stand for providing women with tools for early detection of heart disease.

CONAM Multifamily Partners Fund III Purchases Arise Craig Ranch in McKinney, Texas

Retrieved on: 
Mercoledì, Ottobre 4, 2023
Interior Design, Other Construction & Property, Residential Building & Real Estate, Construction & Property, Urban Planning, REIT, Landscape, Energy Star, Texas Health Resources, Lighting, Partnership, US-75, Dallas North Tollway, Craig Ranch, Southwest Airlines, Multimedia, Development, Walking, University of Texas Southwestern Medical Center, MSA, Restaurant, Baylor University Medical Center, Granite Park Chalet, Methodist Dallas Medical Center, Legacy, Balboa Park, Maple, Stonebriar Centre, HCA Healthcare, Legacy West, Chinese Americans in Dallas–Fort Worth, Shop, Tourism, Southwestern Medical District

CONAM Multifamily Partners Fund III, a discretionary fund sponsored by The CONAM Group (CONAM), is pleased to announce the purchase of Arise Craig Ranch , a 270-unit Class A multi-family community in McKinney, Texas, one of Dallas’ fastest-growing northern suburbs.

Key Points: 
  • CONAM Multifamily Partners Fund III, a discretionary fund sponsored by The CONAM Group (CONAM), is pleased to announce the purchase of Arise Craig Ranch , a 270-unit Class A multi-family community in McKinney, Texas, one of Dallas’ fastest-growing northern suburbs.
  • View the full release here: https://www.businesswire.com/news/home/20231004139108/en/
    Courtesy of The CONAM Group (CONAM) - Arise Craig Ranch is a 270-unit Class A multi-family community in McKinney, Texas, one of Dallas’ fastest-growing northern suburbs.
  • We are very pleased with the additions of Arise Craig Ranch and ALMA On Maple as they close out CONAM’s investment activity for Fund III,” says Jack Cleary, CONAM’s Southeast Acquisitions Director.
  • Situated 30 miles south of Arise Craig Ranch, ALMA On Maple joins the CONAM portfolio after the closing of this asset for a long-term partner.

Step Up Announces Its 25 Mentors of the Year in Honor of Nonprofit's 25th Year of Service

Retrieved on: 
Lunedì, Ottobre 2, 2023
ACT, Morgan Stanley, WE, Ketanji Brown Jackson Supreme Court nomination, New York City Department of Health and Mental Hygiene, The New York Times, Allyson Felix, Boeing, Investment, Marketing, Public, UCLA Anderson School of Management, SAG-AFTRA Foundation, STEP, Woman, Spotify, British Inspiration Awards, GSTQ, Mentorship, MBA, Ariel Investments, Science, Collaboration, National Football League, Warner Music Group, University of Texas Southwestern Medical Center, Dream, Valeisha Butterfield Jones, Cultivation, Care.com, Engineering, Supreme court, Biophysical environment, Step Up, LOS, Jenner & Block, Mathematics, First Republic Bank, Smith College, Character, Accenture, Christian University, Management, Sports equipment, Music, Creative industries, Nursing

LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Step Up, the mentorship nonprofit that guides girls (and those who identify with girlhood) to their success, today announced its first-ever list of 25 Mentors of the Year in honor of the mentorship nonprofit's 25th anniversary. This new distinction is reserved for those who serve as role models in the community for defining and pursuing dreams of success demonstrated through their impactful work, journey, and character. 

Key Points: 
  • LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Step Up, the mentorship nonprofit that guides girls (and those who identify with girlhood) to their success, today announced its first-ever list of 25 Mentors of the Year in honor of the mentorship nonprofit's 25th anniversary.
  • The Mentors of the Year and Next Gen Leaders will be acknowledged at Step Up's upcoming Inspiration Awards, set for October 6 in Los Angeles and November 16 in Chicago.
  • Please find the full list of 25 Mentors of The Year list below.
  • Carla Harris - senior advisor, Morgan Stanley
    Mellody Hobson – president and co-CEO, Ariel Investments
    Build Skills: these mentors demonstrate how to grow our abilities.